TheStreetSweeper in the News The Wall Street Journal: Northern Oil and Gas Shares Plunged: What You Need to Know Barron's: More Trouble for Northern Oil and Gas. Now, the second-hand smoke from this Clarence, New York company here may be poised to kill the average investment portfolio, thanks to: The company last Friday hyped a previously hyped meeting with the Food and Drug Administration … an announcement here ultimately tied to paid promotions and stock dilution.

This hype, in our view, amounts to nothing more than an effort to pump up the stock price. The press release concludes XXII will simply continue with its modified risk tobacco product MRTP application. This appears to be just self-promotion. The company's additional recent promotion came as an announcement about an XXII-sponsored survey on low-nicotine cigarettes.

That's not all, of course. More hype has been puffed out A hype-maker called TheStockExpert pumped out a series of late-week promotional emails, including: Make sure to continue to closely watch XXII for today because we expect to see this one continue its trend of gains today. The real surprise is what some unbelievably kind-hearted third party has paid to get XXII pumped: A week earlier and a month before that, hype outfits called Small Cap Traders and Road Runner Stocks reeled out more promotions: The jaw-dropping total number of promotional campaigns going back to ?

The SEC has warned that paid promotions too often become the key part of pump-and-dump schemes. What does this mean to average earlier shareholders? Dilution of about Seeing your shares get watered down is never a good feeling Meanwhile, the big investment banks are avoiding XXII.

With teams of researchers devoted to in-depth analysis, institutions can offer a level of comfort to individual investors. The absence of these big funds is a big concern. Even more concerning is that institutions are selling their stock in XXII: XXII offers no news, more third-party paid promotions to hype its imaginary news, institutions selling stock and more stock dilution.

The owners of TheStreetSweeper hold a short position in XXII and stand to profit on any future declines in the stock price. As a matter of policy, TheStreetSweeper prohibits members of its editorial team from taking financial positions in the companies that they cover. To contact Sonya Colberg, the author of this story, please send an email to streetsweepereditor yahoo. The company focuses on hydrogen fuel cells for stationary and mobile uses, and hydrogen-generating products.

MeanwhileTheStreetSweeper alerts investors to six top issues ready to burst this overinflated balloon: Major Customer- Investor Sells Stock. CommScope — not only a one-time major shareholder but also a major customer — hits the HYGS sell button … repeatedly. Just since June 1, CommScope has dumped more thanshares of HYGS! Company SEC filingclick to see entire list. CommScope has seen fit to cut its approximate 1. The stock has recently attracted coverage of a paltry two analysts.

According to TipRanks, Mr. Analysts Consistently Overestimate HYGS. Meanwhile, TheStreetSweeper presents the top reasons we believe this smoking stock will get stomped out. Average stockholders have gotten what sounds like a sell signal last Friday from none less than the XXII president and CEO. Another executive may be preparing to sell, too. Another professional promoter, Research Driven Investing, pushed the stock June 7, getting the advertisement on Yahoo.

RDI will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of information in this advertisement ….

A similar outfit called Traders News Source also pushed the stock June 8. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. More promotions occurred in March and April, plus at least half-a-dozen times last year. In fact, since MarchXXII has been the subject of at least 36 massive campaigns by various promoters.

Despite massive losses, getting busted for Medicare fraud and red-flagged broker reports, Cancer Genetics CGIX is watching its stock shoot up. TheStreetSweeper breaks through the smoke and mirrors that obliterate the risky nature of this biological testing company based in Rutherford, New Jersey.

The company just beat down the wall to begin selling a new raft of stock, posing a significant dilution hazard to current shareholders. Depends on two stock sales yearly to keep the doors open. Giants like Labcorp, NeoGenomics offer similar tests. Sole coverage by troubled broker-dealer is a red flag; also foretold the recent stock offering. Prepare for potential watering down of current shares … and plummeting stock price. Meanwhile, consider the top seven reasons this company appears genetically predisposed to destroy shareholder value:.

CGIX is one cash-chomping machine… as shown by the sharp drop in cash and equivalents over the past few years:. Operating income is precipitously dropping. The tan blocks show estimated figures in the second and third quarters:. This situation puts CGIX in a tough spot.

And a funny thing happened. Products include proprietary tests and services, plus non-proprietary tests and laboratory services. The proprietary cancer diagnostic test is, unfortunately, very similar to tests produced by rich giants that have already scratched and clawed their way into the field … leaving little room for CGIX now or in the future. New Age Beverages NBEV has turned into junk food for investment portfolios.

Right now, this functional beverage company is rolling. NBEV has indulged in rolling up other weak companies. Everything looks fine for a while. Then bigger expenses and headaches hit … and often bigger losses … before long, the whole thing may wash into a roaring abyss. This Denver roll-up has gone into a cash-starvation diet that may be resolved with a significant cash raise. Drinks include Live Kombucha, Xing Tea and Aspen Pure, which users can apparently only buy directly from the company.

Below, we compare key profitability ratios for NBEV versus peers. NBEV also loses money, while the others make money. TheStreetSweeper issues an investor warning for Exact Sciences EXAS. That coverage is great.

Meanwhile, consider the top seven reasons we believe Exact Sciences is exactly the wrong investment right now: Company SEC filingTheStreetSweeper. This quarter will be worse. As expenses ramp, EXAS could tap marketable securities.

But why do that if the stock is trading at record highs? Selling stock now makes sense. Revenue comes upon delivery of a test result to the doctor who ordered it. Our laboratory service revenues are generated by performing diagnostic services using our Cologuard test, and the service is completed upon delivery of a test result to an ordering physician. Recent clinical guidance in the Southern Medical Journal compares Cologuard versus the quick, cheap, non-invasive test known as FIT or fecal immunochemical test.

Cologuard is referred to as sDNA below…. In contrast, FIT requires only one stool sample. Patients seem resistant to sample their own stool. We can imagine Mark Cuban squinting and scowling as he asks Titan how last quarter went…. Neither was the previous one, Titan folks would have to say. Though analysts consistently expect losses, quarter after quarter after quarter, in its pre-holiday report Titan actually missed estimates once again.

Analysts thought the company would lose 16 cents per share. Bad enough, of course, but not as bad as what Titan actually lost … 19 cents.

So, turning to Price-to-Cash Flow, Titan is jaw-droppingly expensive: Consistently making no money is, well, really unfortunate. Either you make it or you lose it. Titan is losing money and losing ground to the competition.

The Burlingame, California company is working on technology that shoots electrical pulses at cells in hopes of annihilating tumors. Now, stockholders face shockwaves amplified by the baseless stock action. Meanwhile, TheStreetSweeper weighs in, offering the current points that have this stock pulsing with risks for average stockholders: The influential executive has been adding to his stake and news outlets have reported his frequent filings since then. Below is the recent run-down: Regardless, large institutional investors just do not care.

TheStreetSweeper has seen horror movies like this before. SDC and covers the manufacture and sale of specified OLED display products. Under this agreement, the Company is being paid a license fee, payable in semi-annual installments over the agreement term of 6.

The installments, which are due in the second and fourth quarter of each year, increase on an annual basis over the term of the agreement. The deal put Universal Display on the map in and generated millions in revenue.

But this year … it looks like a wrap. Barriers to Entry Drop. Patents owned by the company are at the brink of expiration. Others hit their year patent protection expiration date as early as next year, as indicated in the SEC filing here. Anybody and everybody will then be able to use the technology. MI is ready to shake up the organic light emitting diode OLED world. Merck has been in OLED chemical production since Merck will naturally go after Apple, Samsung and every other biggie. Merck is among dozens of OLED market players, including Dow Chemical and BASF.

Merck plans to lead the market by With all due respect to Jim Cramer, we disagree with him this time. But just as importantly, Mr. The stock, in our view, is now teetering at the brink of rapid decline. Five key factors amping the risk for stockholders include: The company will have to pay those loans as well as ongoing expenses TheStreetSweeper releases an update on Clean Diesel Technologies CDTI.

This Oxnard, California automotive emissions control company's stock has apparently reacted to a strange pump piece published yesterday. The piece is particularly concerning because the promoter first says it received no compensation and at another point states that its pieces are bought-and-paid for. Federal regulators recently filed charges against firms and individuals connected with fraudulent promotion of stocks.

Below is the tweet from the paid advertiser, directing people to the advertiser's site: The link to the promotional piece is here. The promoter's report ignores substantial risks affecting CDTI, including: CDTI is a cash-burn machine, running on empty. So at t his point, it would have barely enough cash to operate another quarter. A cash raise - perhaps stock selling or a debt tap - appears imminent. More raises are likely ahead, too, with the potential to water down existing stock.

Going concern issues threaten the business. The stock rose recently - not on the merits of the company - but on paid advertisements. Catalyst revenue - the chief source of revenue - has dropped as the chief customer backs away. CDTI reports that entire revenue will end next year. Revenue faces additional risk as President Trump has clearly signaled he wants cuts to emissions control regulations, thus reduced need for CDTI products.

So we explain the downside risks associated with this stock. But the pump piece author talks unconvincingly about financial figures that seemed fine and finally concludes that they don't really know what's going on with the stock We will be updating our subscribers as soon as we know more. For the latest updates on CDTI, sign up below!

It looks as though Insider Financial simply wants the reader to become a subscriber. Oddly, Insider Financial states it has received no compensation for the piece. But the site disclaimer indicates otherwise: Disclaimer — This newsletter is a paid advertisementnot a recommendation nor an offer to buy or sell securities.

This newsletter is owned, operated and edited by Archangel Media Consulting, LLC. Our business model is to be financially compensated to market and promote small public companies.

As Clean Diesel Technologies CDTI attempts to leave a terrible earnings report behind, a series of slippery mudholes stretch out in the road ahead.

The Oxnard, California company focuses on emission control products for light trucks and cars. But TheStreetSweeper expects the stock to fall face down in one or more of the following five mud puddles: At this point, Clean Diesel is practically running on fumes.

It should have barely enough cash to operate another quarter. The snapshot below summarizes the cash and declining revenue problem: And since it historically operates in the red, it will continue to search for operating cash via debt deals or potentially dilutive stock sales well into the foreseeable future.

Big Losses, Going Concern: Shareholders will get a peek at the salary of the executives who are steering this wreck…. That kind of market valuation makes no sense for a risky no-product, old-patent, minimal-revenue, professionally promoted company whose key stockholder was investigated for manipulating stocks. The Huntersville, North Carolina company is focused on an RF filter patent filed by CEO Jeffrey Shealy in The company hopes its older technology may eventually compete with well-funded, established companies whose products help wireless carriers reduce dropped calls.

Investors may find the website here of the company, which has not answered our numerous calls and emails requesting comment.

However, the Securities and Exchange Commission is considering the information we've submitted. In this second part of an investigative series Part 1 is hereTheStreetSweeper presents additional reasons we consider Akoustis stock a major risk to investment portfolios.

Our Patent Portfolio Isn't Worth Much. Regulatory filings state just what Akoustis thinks its patent portfolio is worth Yet this patent portfolio - worth about as much as a fancy pickup - is driving the whole company. The stock has also recently risen on the wings of an Akoustis announcement of plans to buy an old upstate New York factory referred to as STC-MEM.

TheStreetSweeper issues an investigative report on Akoustis Technologies AKTS. The company currently lacks a commercial product, filter plant, distribution plan and ready customers. The company is based on a year-old patent for a filter designed to help carriers improve battery life and cut dropped calls. Tompkins and business partner Adam Gottbetter were investigated for possible stock manipulation of reverse merged companies.

The dates are nearly two years off. Tompkins manages his Akoustis ownership from luxurious quarters in Switzerland, filings indicate. TheStreetSweeper has filed a verbal and written complaint with the Securities and Exchange Commission regarding Akoustis activities. The lofty stock accelerated after the NASDAQ uplisting on March The stock price continued its flight path after several highly optimistic Akoustis reports by a paid promoter.

News of a pending filter factory and incentive possibilities were misunderstood and apparently further pushed the stock price. CEO Jeffrey Shealy smiled and rang the NASDAQ closing bell March 22, Three months earlier, he had joined other insiders who registered to sell their stock.

He is prepared to sellshares of his company stock. The company will receive no proceeds. Akoustis burns millions of bucks quarterly. In a couple of quarters at most, we believe there will be a significant dilutive stock offering in order to generate operating cash.

Our repeated calls to the CEO went to an answering machine and weren't returned. Recent reverse-merger, Akoustis Technologies, Inc. AKTSwe believe is partially controlled by a hard-partying but secretive man once investigated for possible stock manipulation of reverse merged companies. This Canadian resident quietly rides herd over Akoustis from his luxurious apartment in Switzerland, SEC filings indicate.

But the market is unaware of that interest in this company with no meaningful revenue, no commercial product, a single patent and no clear execution route.

Indeed, the over-the-counter stock uplisted to the NASDAQ a few weeks ago and caught fire. Meanwhile, we present 12 risks associated with this Huntersville, North Carolina radio-frequency filter developer for carriers. Akoustis Technologies took the cheap and easy route to the public market in May by merging into a public shell company - a Russian shell dreaming of making mobile games for Apple.

The shell existed as a one-man band with Ivan Krikun at the lead. He juggled seven corporate positions while the band banged out a melody of zero revenue, big losses and auditors' warnings that " going concern " issues could kill the whole thing. The business plan fell apart. The current rendition of Akoustis is very similar: Uncertain pathway to execution.

Behind the scenes, a deal guy may be adding Akoustis to his collection of stock toys Mysterious Deal Guy; Offshore Accounts. We believe the man behind the Akoustis curtain, Mark N. Tompkins, has been a moving force behind both the current company and the Russian-owned shell.

His involvement is not just interesting. It's a risk factor. Infederal prosecutors in Manhattan investigated whether Mr. Tompkins wasn't charged but the investigation did shine light on Mr. Tompkins and his moneymaking system of promoting stocks. Divorce proceedings in and investigators' subpoenas revealed a living-life-to-its-fullest, but cautious man who said he didn't maintain business records and warned associates never to email him. Tompkins reportedly owned 20 brokerage accounts at the time and nine offshore bank accounts.

TheStreetSweeper releases an investor alert regarding Pulse Biosciences PLSE. Second Sight Medical Product EYES is one example. So Pulse is the same company it was on that warm, sunny day last May 18 when the stock first began trading on the Nasdaq. Pulse has been digging the hole deeper and deeper because new medical device companies simply get doggone expensive just swaying in place. Much less stepping ahead. But the real money-gobbling begins if the company ever progresses.

Then it would have to add massive costs for everything from clinical trials, to making the device to marketing and distribution. Competitors in the cancer market include Juno Therapeutics JUNO and Kite Pharma KITE. Research and development is the lifeblood of all the biotechs.

But Juno spent 18 times more than Pulse on research and development. SEC filingsMarketwatch, TheStreetSweeper. Clearly Pulse will have to spend much more to catch up with Juno and Kite. And those two have barely stepped on the gas toward the accelerated spending required to fuel a biotech. But even spending hundreds-of-millions on research and development can't assure success or profit. These companies are doing much better than Pulse as far as revenue and cash.

But despite their experience, Juno and Kite are still very risky and sickly, too. Company SEC filings, year's end cash, TheStreetSweeper. MarketwatchYahooTheStreetSweeper; ELOS last available numbers. Biotech carries no guarantees, other than you can bet on burning plenty of cash chasing a product that may or may not ever become reality. Juno shares recently declined again when the company announced it would not progress its cancer treatment due to "unfortunate and unexpected toxicity.

TheStreetSweeper issues an alert for any investor considering stock in Care. The stock has recently ripped to an unsustainable level and is now dropping back a bit. We believe the current decline may be the beginning of a larger, well-deserved unraveling.

The Waltham, Massachusetts company connects caregivers, such as babysitters or tutors, and families through a website. The stock ran way ahead of the company's true value, in our view, after Care. In a year, insiders have dumped 4. An attorney general is looking into complaints surrounding Care. Consumers have lodged more than complaints against the company. Investors may find the company website here.

Meanwhile, TheStreetSweeper presents the top reasons we think Care. TheStreetSweeper issues an investor alert about the quiet furor blowing up around Foundation Medicine FMI. The Cambridge, Massachusetts company spun out its initial public offering in September Since inception eight years ago, the genomic profile testing company has lost money Meanwhile, TheStreetSweeper highlights the top issues that we believe will soon crimp this stock. Stockholders' Earnings Disintegrate, Revenue Drops.

Stockholders are suffering a significant decline in earnings from Foundation. From quarter one to quarter four, losses increased a miserable Along with these big losses, Foundation's revenue is declining, too: CNN MoneyTheStreetSweeper. Along with lower revenue and higher losses, gross margins have plummeted It may be that traders misunderstood this line: But Foundation actually said that the parallel review process will end in the second half ofthey think.

Investors may soon find themselves checking the pulse of Pulse Biosciences PLSE But right now the Burlingame, California company is managing to pull in unwary investors. The company is working on a device that uses pulsed electric fields to possibly treat solid tumors and skin problems such as warts. Stock in the zero-revenue company began trading on the Nasdaq in May Find other viewpoints here and the company website here.

Meanwhile, TheStreetSweeper lists the top four reasons we believe the stock is at risk of suddenly pulsing downward: When the company IPOd last May, some stock was locked up but has been freely tradable since November.

However, a massive 4. Especially if sold en masse, those millions of shares have the potential to significantly water down shares owned by existing stockholders. The stock is set to be unlocked for sale the first week of May So we expect many more stock sales in the future MDB Capital Group was the company's underwriter MDB installed its own director as Pulse chairman of the board. But does MDB's track record justify the high cost to Pulse and its investors?

Well, things have turned out poorly before for many stocks with strong MDB participation. Just a few examples include: The chart below shows what has happened to the stock.

TheStreetSweeper issues a warning for investors of Professional Diversity Network IPDN. IPDN stock has gone Wild, Wild West following widely misunderstood investor announcements … including one regarding a Chinese investment group that we found lists its business address as a post office box on an island.

Now TheStreetSweeper believes this stock is positioned to get shot down to size. The lender holding that stock may now sell any or all shares. Stock typically jumps initially before dropping back to pre-split levels or worse. Investors may find other viewpoints here and the IPDN website here. Meanwhile, let's examine five good reasons to dump this stock now: Just Set Me Free. IPDN has set up the paperwork so a stockholder, White Winston Select, can sell off the lion's share of its stock Now the lender wants to unload some stock.

Meanwhile, the company rips through millions of dollars, subtly pushing average stockholders closer to watching their shares get watered down in the future. Formerly called You On Demand Holdings, the video-on-demand provider operates primarily in China. After numerous business changes, Wecast now hopes to develop a consumer management platform for businesses and consumers The other company sells scooters and furniture Wecast wants investors to believe that it's really a tech company This company can't decide on or focus on a business.

Investors may find other viewpoints here and the company website here. Meanwhile, TheStreetSweeper presents the top nine reasons Wecast is a monumental risk. Rat's Nest of Related Party Deals. The stock ran up following two mergers with companies owned by Wecast's chairman. Wecast announced the Feb.

The company name was changed from You On Demand to Wecast Network Inc. Products is owned by Sun Video. Sun is owned by chairman Bruno Wu. This debt deal is off if Sun Video doesn't reach its target. The deal sounds fishy to us. Wecast gets the Wide Angle shares from BT Capital Global Limited Chairman Bruno Wu and his Sun Seven Stars.

Wecast's chairman threw in his company, Wide Angle, for free. Why on earth would he do that? It could be that Wide Angle is worthless. It could be the chairman wants to promote the stock. Who's Your Daddy And You Say He's Selling Scooters? Let's look at the two companies, owned by the chairman, which are intricately bound to Wecast. Northern Dynasty Minerals NAK may be using Trump tales to hook investors. These claims appear to be nothing but hype used in an effort to pump up the stock.

But the "Pebble" project has been stalled for three years amid a firestorm of opposition and a lawsuit with regulators. Northern sued the Environmental Protection Agency in after the agency used a rare veto initiative to block mine construction before the company had applied for a federal permit. And the EPA indicated to TheStreetSweeper on Feb. Northern's public comments were used by Bloomberg for a Jan.

So the CEO said that Northern has Trump's backing and the new administration has "a desire to permit Pebble? The company has ignored TheStreetSweeper's numerous requests for comment. But a reliable source and a StreetSweeper research provider did talk to investor relations, confirmed through Jan.

Investor relations said no one with Northern ever spoke to the Trump team or the incoming EPA team. And operations have been expanding in Mexico as a brand-new wheel plant there reaches full production.

But after two whirlwind weeks into his presidency, Mr. Trump is cracking his knuckles over all things Mexican. I think your military is scared. As US-Mexican tensions escalate, Superior is feeling the blows ….

President Trump has just signed an executive order to build a wall along the Mexican border. And margins have been in free-fall for years. The average yearly rate of decline is So Superior enters the Trump era with deteriorating margins that prevent the company from a sustainable competitive edge.

And the risks just keep growing for this company whose strategic priority is to increase Mexican manufacturing capacity ….

President Trump made dismantling NAFTA a central theme of his campaign, calling NAFTA " the worst trade deal in the history of the country. But NAFTA smoothed the pathway for Superior to expand into Mexico, according to its website. Within days, the president is expected to sign an executive order to renegotiate NAFTA. The agreement eliminated most trade tariffs between the U. Since inception eight years ago, BioSig Technologies BSGM has gone nowhere fast BioSig is a non-revenue, cash-gobbling Minneapolis, Minnesota company focused on a non-FDA-approved product.

The PURE EP System is designed to display data during an electrocardiogram or EKG. Now this dangerous stock has reached a level that we believe leaves only downside ahead. TheStreetSweeper presents the top risks that challenge a BioSig investment: Yesterday morning, many folks' inboxes were treated to this Bio Sig come-on: The next BioSig promo surge came just a couple of hours later: Here's more hype that landed in the morning's email: These emails are paid promotions.

Just the kind of thing you'd never see trumpeting a stable company with viable products. Magellan Petroleum MPET stock has rocketed into treacherous territory as the market misunderstands the extreme risks ready to slam the shares. The Denver, Colorado company has abandoned the oil business amid plans to reverse merge with Tellurian Investments and eventually build a liquefied natural gas terminal. Investors may find other viewpoints here.

Meanwhile, TheStreetSweeper shares the eight top risks expected to annihilate this stock: Investors seem excited right now about the planned reverse take-over of private company Tellurian Investments into Magellan. Tellurian is the grudge company created by Charif Souki shortly after Cheniere Energy kicked the former chief executive out the door in late Souki wants the merged company to build a multi-billion-dollar natural gas liquefaction plant in Louisiana.

Ironically, the measly revenue came from Parallax Enterprises, which has been sued by Mr. Cheniere had loaned Parallax money as the two made plans for a liquefaction plant joint venture. Meanwhile, there has been substantial doubt about Magellan's ability to continue operating.

Company filings say Tellurian is in bad shape, too. Magellan Stockholders' Ownership Decline. Under terms of the merger awaiting shareholder approval in February, each share of Tellurian will be converted into 1.

Former Tellurian investors will walk away with almost the entire company Magellan stockholders will find themselves on the wrong side of this deal. They will be left with just a sliver of the company As it turns company control over to Tellurian shareholders, the merger will dramatically increase Magellan's current outstanding share count of 5.

At the current lofty share price, Magellan winds up with an unconscionable market valuation: Company SEC filingTheStreetSweeper assuming post-merger estimates. In the smoky world of marijuana, MassRoots MSRT shares have floated skyward as promoters puff out nearly three-quarters-of-a million-dollars worth of promotional campaigns.

The idea of connecting pot heads arose back in among a group of something friends. Meanwhile, TheStreetSweeper presents the highlights as we begin to dig into this risky stock. TheStreetSweeper has requested an interview with MassRoots and a couple of promoters to discuss who's behind the promotions and why.

The companies have not responded. Promoters pushed out 10 of these MassRoots "awareness" campaigns in December, according to data gleaned from stockpromoters. The snapshot below shows two recent promos. And the hits just keep coming As recently as Thursday, Jan. The disclosure get free credits xbox live the promo below warns that the promoters may hold and liquidate stock positions in the advertised company without notice, even after they have made positive comments about the company.

Promoters sometimes play fast and loose with the facts in email newsletters designed to build excitement definition of barter trade system a stock. Below are snippets from a Dec. Despite the promoter's claim, MassRoots app is not available on Google Play, as we explain in more depth below Google Play dropped the MassRoots app in November, effectively blocking one of the company's most vital access points to kiss forex trading Boring ol' Skyline Corp.

SKY has once again hitched a ride on the coattails of a flashy multi-billion-dollar UK company with nearly the same ticker symbol. Booming Skyline stock is now swooning a bit as the market begins to understand that news of a plan to take over media giant Sky Plc may have been inadvertently advancing Skyline stock.

Meanwhile, TheStreetSweeper presents the top issues threatening those invested in the mobile home manufacturer. Today's Sky Plc news did erroneously end up in Skyline's news feed, once again: L News Appears Stock brokers in iraq SKY's News Feed.

Skyline stock took off on a rollercoaster ride last Friday. We believe the stock gained much of its strength that day because Skyline's news feed contained news that Rupert Murdoch's 21st Century Fox had made a bid to buy Sky Plc media Skyline's stock had been headed downward until about an hour after Sky's news erroneously appeared in Skyline's news feed, at which time the stock began to climb: Investors who took a cursory glance at Skyline's news feed may not have taken the time to understand the vast differences between the two companies The ticker symbol is SKY.

Sky Plc predictably shot up on the 21st Century Fox bid news: But the news that understandably spurred Sky Plc. So the blurb is deceptive when it is part of the Yahoo Finance news feed for Skyline. Now it needs to be deleted. We believe this is the second time a Skyline stock surge may be linked to the wrong story getting into Skyline's news feed. Last summer, we wrote about investors apparently buying Skyline on the news that Sky media planned to launch a new TV channel in the UK.

One line in the Yahoo story may have generated even more misplaced frenzy: And this time, the Sky Plc news is not in Skyline's news feed. Meanwhile, prior to the recent misplaced media buzz, Skyline's stock price had begun a general uptrend that seems to coincide with analyst commentary for Sky Plc media. TheStreetSweeper issues an investor alert for Ingram Micro IM. Under the buyout deal, Ingram Micro would become a subsidiary of China-based HNA Group specializing in logistics, aviation, financial services and tourism.

HNA is a major shareholder of Tianjin Tianhai, which focuses on shipping, logistics and financing. California-based Ingram Micro would be outside the Chinese companies' core business because it is an information technology company. Below is a partial copy of the photographed document said to be from the People's Bank of China conference record, indicating the central government likely has already passed the regulation on to the bank.

It's not perfectly clear whether the restrictions would institute an actual ban or more intensive scrutinybut the economic issues demand that China reduce its capital outflow: Translated, the relevant portions state: This is primarily targeting six types of foreign investments through supervision and control. Filing and approvals are not permitted unless with the approval of the appropriate departments.

The measures have been approved by the State Bisnis forex halal apa haram, the Ministry of Commerce, Development and Reform Commission is responsible for the implementation of concrete measures will soon be issued.

Six categories of business include: Direct investments of partnerships. Using subsidiaries to acquire foreign companies. Chinese investment groups taking foreign listed Chinese companies private. With regards to existing investment projects which are approved by the National Development and Reform Commission, the guideline mentioned above should be followed. Our interpretation, along with that of reputable third-party Chinese speakers, is that other government departments must follow the "no filings" and "no approvals" guidelines.

The exception would be ruger american rifle tactical stocks undefined "relevant departments" have already approved the foreign investment. The South China Morning Post states the ban would be effective from now until September of next year. The declining value of the yuan, as documented in numerous news storieshas pressured China to cut down on assets flowing out of that country.

Since the documents are in Chinese and have just been leaked, we believe very few U. Other Chinese Buy-Outs Suffer. The leaked documents reached the ears of some investors in Changzhou, China-based Trina Solar TSLa billion-dollar company which sells solar products to power plants and grid operators. Trina called a Dec. TheStreetSweeper issues an alert for investors of Airgain AIRGa recent IPO that is prepared to wipe away a ton of shareholders' stock value.

Investors bought into the wireless network antenna distributor when it first offered its stock to the public last summer. But now the company is planning a massive follow-on offering. Investors are witnessing the relative calm before can you make money on yahoo contributor network storm of shares hit the market and spark a stock price decline.

Below are TheStreetSweeper's top six reasons this stock is looking to get smashed: Airgain filed a registration statement at 5 p. At the current price, about 2. Why This Follow-On Offering Is Dangerous. The price of a stock typically drops after a secondary offering because IPO investors' level of ownership decreases with the increase in shareholder base.

The chart below demonstrates how a seemingly small jump in outstanding shares - from 7. And investors have just been exposed to the possibility of watered down shares Dilution Potential Begins Now. For its IPO in August, Airgain registered 1. Now the underwriter has just released the lockup restrictions, effective after market close Nov. So all those shares that would have been locked up a couple more months have been set free so those lucky shareholders - including forex drawdown meaning and directors - can sell their stock.

Fenix Parts FENX has now entered the realm of "The Walking Dead. Ruble forex chart, Fenix is a little like the TV zombies who have taken over the world, mindlessly wandering from one horrifying cliffhanger to the next.

While investors may find other viewpoints hereTheStreetSweeper releases the five top reasons to avoid this unfolding investor nightmare. The Securities and Exchange Commission has launched an investigation into Fenix's financial reports. Fenix disclosed on Oct. The SEC seems to be scrutinizing the company's accounting methods, internal controls and recent change in auditors on July 8, auditor BPO was dismisseda red flag event.

The filing of a subpoena indicates the difference between market value and book value of equity is now a formal SEC investigation, according to the SEC's " How Investigations Work. Fenix rolled up 11 companies into one and completed its initial public offering in May As TheStreetSweeper has described many times before, things don't always go too well with roll-ups.

Fenix hinted at big troubles ahead through its numerous notices of delayed financial reports. In fact, since the summer of how to make money betting on horse racing, Fenix has filed notice that its yearly or quarterly financial reports would be late a total of six times. The most recent - the delay of the third quarter financial report - was filed Nov.

The financial report is also apparently on hold because the company was "not in compliance with a certain loan covenant. Here's the broken covenant reference: This delay could not have been eliminated by the Company without unreasonable effort and expense.

The Company has been in discussions with the lender with respect to the written waiver, which the Company expects to receive. So the covenant breach is a bombshell because investors are on notice now that Fenix's track record will likely make it more difficult for the company to borrow money. Northern Dynasty Minerals NAK is interested in mining But the unofficial target is unwary stockholders.

Now that the stock is overbought amid a stream of hopes and dreams for a 1 minute taxes on binary option trading mine, early buyers should be ready to cut bait. Some significant investors have gotten fed up and dumped all of their shares in Northern. So big sell-outs begin TheStreetSweeper's list of reasons we believe this stock is primed to drop long before the studies or permits are ever completed for the Pebble Mine project.

Investors should not be fooled by this Canada-based shell company's flaunted "Pebble Partnership. In fact, companies have backed out of the ill-conceived plan like crazy. In FebruaryMitsubishi divested every single share of Northern.

But Rio Tinto divested all shares in April Following its investment in and six years of paying for lawyers and studies for the Pebble project, Anglo gave up its half of all rights to the project in December More recently, Northern has been able to attract a few no-name investors. But even some of those are selling out. So Northern will find it difficult if not impossible to find large reputable investors after losing so many significant partners.

While Northern has been unable to generate much more than litigation with the Environmental Protection Agency, it has generated plenty of losses. The figures below are in thousands of dollars. The company handed out 6. The company is important to insiders for another reason The company is paying millions to a private company owned by Northern's leaders. President-elect Donald Trump's dump Obamacare pledge could be Teladoc's code blue.

Obamacare has been a luscious target for companies like Teladoc TDOCreleasing a veritable army of telemedicine companies onto Wall Street in the last few years. In a press release titled "Obamacare creates greater need for telehealth innovations," Teledoc emphasized Obamacare or the Affordable Care Act ACA as a telehealth driver. The release announced new board members David B. Senator William Frist, M. Teladoc is an innovative and effective solution for addressing the current access barriers to primary care And in its annual report, Teladoc wrote of the risks of ACA: The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown, but may adversely affect our business, financial condition and results of operations.

Our revenue is dependent on the healthcare industry and could be affected by changes in healthcare spending and policy. The healthcare industry earn money by receiving sms on mobile subject to changing political, regulatory and other influences. The PPACA made major changes in how healthcare is delivered and reimbursed, and increased access to health insurance benefits to the uninsured and underinsured population of the United States.

But the catalyst a corporation that did nothing but buyout the stock of other companies a "catastrophe," according to the president-elect. Trump pledged that after he won the election, he would convene a special session of Congress to repeal the Stick rpg 2 how to get tons of money And we will do it.

And we will do it very, very quickly," he said in a Nov. The day after the election, Republican leaders promised that they will "hit the ground running. Investors may find other viewpoints on Teladoc here. Meanwhile, TheStreetSweeper takes a closer look at the Teladoc foundation that is precariously propped up by Obamacare.

Teladoc's business of connecting patients to doctors by webcam, app or phone has limped along for 14 years on loans plus private and public stock offerings - losing money since inception. And as many assumed Obamacare would be relatively safe with Hillary Clinton in the White House, company managers said that cash and borrowings would last "as we exit Still, Teladoc prepared to plug any cash hole by issuing more stock.

The shelf of shares registered Sept. From time to time after the effective date of this registration statement. So at the current stock price, Teladoc would be able to sell about 17 million shares. This means more than another third of shares outstanding could hit the market. The registration, declared effective by the Securities and Exchange Commission on Oct. Sellers will get all proceeds. Not one dime will go to the company. Analysts Expect More Of The Same.

Normally optimistic analysts offer a rather poor prognosis for this year and next for Teladoc: Seeking AlphaSEC filingsTheStreetSweeper. While Skyline Medical SKLN hasn't turned a penny's profit in 14 years, it's sure learned how to dilute stockholders' shares. Shares have blasted up recently, placing the medical device company's quivering finger on the trigger to continue draining share value.

Here's a bird's eye view of the reasons Skyline is a highly risky investment: Skyline is low-cash, high-cash-burn and has sold only one unit since It funds operations solely on a loan, convertible debt and stock offerings. The company is under threat of being delisted from Nasdaq. Those shares can be sold at any moment, representing a significant dilution event. The firm depends on reverse stock splits and professional stock promoters to boost the stock derivatives market stock exchange. Skyline repeatedly touts an unfortunate Polish-American partner; the market falls for it.

Meanwhile, let's look more closely at the factors conspiring to dump this stock. Skyline had always been in serious financial straits but things had grown much worse by the end of last quarter.

Skyline had given up on even trying to sell its surgical drain product Streamway FMS. In the arbitrage in binary options demo first half ofthey hadn't sold a single unit. The ramp up in our sales efforts following our public offering have not yet resulted in sales of units. Skyline's cash had predictably tanked and the burn was hot and high: Skyline stumbled and fell at the very beginning.

US History Ch. 6 Review Flashcards | Quizlet

The company first tried to sell shares in the public market in September Not long after Skyline's delayed offering, Nasdaq warnings arrived saying the stock was at risk of losing its listing. That was no surprise because at times, investors could have picked up five or even 20 shares of Skyline for the price of a latte.

Carl Schwartz, a dentist and then-interim CEO, said during a September update-proxy conference call that shareholders needed to approve three proxy items, including a proposed reverse split. The company simply didn't have the luxury of time: Shareholders approved the measure. They understood all too well that a delisting would push the stock to the dreaded over-the-counter bulletin board where sickly companies typically go to die. Yahoo FinanceTheStreetSweeper.

The desperate measure didn't change the value of the stock one bit. These reverse splits increase the stock price awhile and later serve as an ugly footnote to companies that go on to under perform. So Skyline appears to be perfectly positioned to weaken the value of stockholders' shares Watch For Diluting Shares. Like the evil robotic transformer Starscream ,TransEnterix TRXC just keeps transforming itself, returning to the battlefield again and again.

Each time the company switches course, it strings investors along for a long, thrilling build-up followed by yet another dramatic failure.

Though the experimental surgical robot company has been so busy rebooting, sales have been razor-thin and completely absent in So we believe this newest transformation will ultimately send this Morrisville, North Carolina company flying into the trash heap, dragging unwary stockholders along for the ride. Meanwhile, catch the top eight reasons TheStreetSweeper would like to chuck this stock now And this gag-worthy video probably pulled in a few folks: Blue Horse Shoe StocksPenny Stock News and Biotech Insider Alert have all jumped into the promotional pandemonium.

Such promotions, often paid for by some mysterious third-parties, are always red flags. Real companies with real products or at least real promise don't depend on gags and hype. That sort of promotional effort is needed to draw in new, unwary retail investors when a company fails again and again and again The company entered the public market via a reverse merger with SafeStitch in September that cost That stock-and-cash deal went for a company with virtually no sales, property or assets.

That's quite the deal, especially considering that TransEnterix actually said in a letter to the Securities and Exchange Commission: The company's Spider surgical system, a manual laparoscopic system, got cleared in Europe in But doctors didn't like the Spider and sales were almost nonexistent.

Spider was discontinued on Dec. SafeStitch had received FDA clearance to market its hernia repair stapler, AMID HFD, inand also CE Mark approval in Europe. Sales began and stopped in After again getting FDA clearance inUS sales resumed. But no royalties were paid, implying no sales, in or under TransEnterix' watch. AMID was discontinued by Dec. The FDA recently handed Failure Number 4 to TransEnterix when it rejected the company's application to sell the SurgiBot robot system in the U.

The company announced the rejection on April 20, Ekso Bionics Holdings EKSO has been involved with the colorful Adam S. Gottbetter, known for nimble PIPE financing, a quick song with British group Squeeze YouTube video of Adam Gottbetter singing "Take Me, I'm Yours" with Squeeze.

Gottbetter became a key figure behind Ekso's private placement offering in January and February - Mr. But the good times came to a screeching halt.

Seven months after Ekso's PIPE, Mr. His guilty plea was in connection with schemes to manipulate three other companies' stock "with a view to selling his own shares at a profit. The Securities and Exchange Commission had this to say about Ekso's former investment banker: Gottbetter orchestrated promotional campaigns that touted the prospects of microcap companies and enticed investors to buy their stock at inflated prices so he and his cohorts could sell shares they controlled and reap massive profits.

When the trade publication QMed wrote about Mr. But Ekso apparently did not break ties with Mr. Gottbetter's law firm after his plea. In the company's April filing regarding Ekso's private offering, we see that Mr. The SEC broke ties with the attorney last year due to the SEC complaint and Mr. In a remedial action dated June 23,the SEC suspended Mr.

Gottbetter from practicing before the commission as an attorney: Meanwhile, TheStreetSweeper presents an executive summary on the Ekso investment risks: In an August stock sale, Ekso greatly reduced the price of warrants and preferred shares, which may pose potential dilution following the Nov.

Also, anothershare unlock occurs on Dec. Now we'll step back four years, when the investment risks were beginning to form. Ekso took a rather unconventional route to getting listed on the Nasdaq.

It began with PN Med Group, a company operating out of its president's home in Santiago, Chile. The two-person company planned to use the president's car to distribute medical supplies made in China to clinics in Chile.

This sort of shell company is just what companies look for when they're planning the cheap, fast alternative to going public. So Ekso spotted PN Med. Then the stock price got predictably hammered in the Aug. Now this Richmond, California exoskeleton maker just continues to heap risk on top of risk Adjusted Prices Favor Insiders, Dilution Looms For Average Shareholders.

The company greatly lowered the price at which both warrants and preferred shares can be converted to common stock. The filing includes this ominous note: So these cheap shares owned by insiders will be released from the day lock-up about Nov. Partners Switch To Rival Technologies.

TheStreetSweeper issues a critical alert for Resolute Energy Corp. The Denver, Colorado-based oil and gas company's stock blew up to the year's highafter announcing an acquisition and millions of dollars of new debt. TheStreetSweeper highlights the key reasons we consider this stock very, very risky right now.

We might wonder where they came up with all that money. Well, REN is able to accumulated another 3, acres in the Nassim nicholas taleb quotations on stock market Basin by tapping its revolving credit facility and cranking out some new preferred stock.

The owners of the 62, shares of new preferred stock will be eligible for dividends that common stockholders will not enjoy. So the stock is currently trading above the initial conversion price, meaning dilution for existing shareholders.

These properties "contain estimated proved reserves of 6. So REN has spent about three times the estimated value of reserves for production that may or may not pan out. The enormous stock rally appears to be in part due to a short squeeze.

The market must have been smoking weed when it ran up the stock in 22nd Century Group XXII to the highest levels of the year. The cigarette company - which shares space in a Clarence, N. The company is researching genetically engineered cannabis but focuses on genetically modifying tobacco to produce high and low nicotine products. The main products include high-nicotine and low-nicotine cigarettes called Red Sun and Magic, very low nicotine cigarette Brand A and very high nicotine cigarette Brand B, Spectrum cigarettes used in research and the X smoking cessation aid.

Despite the stock rally, Futures quotes amibroker has been swirling within a smoky venue of paid promotions - a lawsuit blocking key market entrance - heavy cash burn - poor financials - looming warrants - failed study real option brand equity - likely inability to get modified risk tobacco product MRTP labeling - and expected inability to nab a partner for phase 3 testing.

Meanwhile, TheStreetSweeper highlights the top reasons we think XXII will end up burning investors: Paid for by third parties. XXII promotions consist of a stunning 14 campaigns this year, with most hype emailed to investors in May. Many of these promotions suggest XXII could get MRTP labeling. That's modified risk tobacco product labeling from the Food and Drug Administration. The labeling would be a key marketing tool because a tobacco company can't legally make reduced risk claims without it.

Despite the promotions, much evidence suggests that XXII will not get MRTP labeling XXII Failed Study, Swedish Experience Foretell Doom. It's highly unlikely XXII will get that desirable labeling. First, the company has failed to advance its one and only phase 2 study. The study of the smoking cessation product called X has been inactive for five years: US National Institutes of Health. Yet Swedish Match, a Stockholm-based company, is in the midst of about 70 active or completed studies for its products: But with all that data for the FDA to consider, even Swedish Match has failed to secure MRTP approval for its various finely ground smokeless tobacco products thus far.

So we can't imagine how XXII - without a single completed study - can possibly expect approval of its MRTP application. XXII realizes that MRTP label depends on getting at least one study completed. The company doesn't have that kind of money. Also the company runs through millions and millions of dollars every six months. A partner would want some legitimate hope that phase 3 might succeed. Though most investors don't know it, the study was dropped years ago after phase 2 failed to show any difference in the four-week period between X and conventional cigarettes: We didn't think so.

Unfortunately, Open market exchange rate pak rupee track record with investors isn't too hot, anyway Ocean Power Technologies OPTT has been riding a wave of momentum trading activity.

Since mid-July it's been a lot of fun. But TheStreetSweeper has spotted ferocious waves swelling up on the horizon And OPTT is careening toward a teeth-jarring wipe out. OPTT began operating two decades ago and still hasn't figured out how to commercialize its system of generating electricity from ocean waves.

On the surface, OPTT's virtually non-existent revenues appear to depend upon the government. Really though, stock offerings and debt have kept the company afloat.

It closed two stock deals last quarter but is left with no committed sources of equity or debt financing right now. Meanwhile, OPTT has figured out how to attract a Securities and Exchange Commission investigation The stock is flying right now, partially because the market doesn't understand the insignificance of the September 13 announcement. The company hopes to develop a power buoy with the U. Office of Naval Research. The initial phase won't be complete until early June Let's look at nine factors TheStreetSweeper believes will dunk this stock.

Money Flies Out The Door Month After Month, Year After Year. Company SEC filing, TheStreetSweeper. The financials are so awful that auditors say it's highly doubtful the company can even continue to operate. Investors On The Line.

OPTT warns that it can't seem to stop burning up money and shareholders' investment may be lost: In fact, the potential for diluting OPTT stock once again could happen as soon as November Tragedy, Lawsuit, Dilution Overhanging. The stock dilution threat is just around the corner, depending on a federal judge's approval of settlement terms of a consolidated lawsuit aimed at OPTT. OPTT will also hand overshares under the current terms. Everyday Health EVDY is looking so pale that it may be secretly looking up its symptoms on rival website, WebMD.

Everyday had never exactly been the picture of health. Investors may find other viewpoints here plus additional risks and background here. Now let's look at why we think this healthcare search site needs to call the doctor. Ten years ago, WebMD was part of Google's experimental program to help improve health search results. The experiment worked and WebMD became a popular site for consumers to diagnose their own illnesses.

Before long, the Mayo Clinic developed its own well-recognized symptom checker. Everyday Health and other content aggregators rushed in and began offering their solutions. The problem is that they must depend on Google searches because they aren't recognized brands. Now a decade later Google wants to keep eyeballs glued to its own pages rather than rushing them away to the content aggregators.

Google began this effort in June, when it rolled out a new symptom search for Androids and Apple phones or tablets. Now this mobile platform is pushing Google ahead of the game as more and more people switch from PC to smartphone searches.

A corporation that did nothing but buyout the stock of other companies Health and other content providers are dependent on Google, the No. Get strong Google results or die.

Other risks are building right behind those posed by Google's new symptom search, including: Doctors are helping with Everyday Health's symptom lookup but most content is by writers who aren't doctors.

Today's Stock Market News and Analysis - dakoxok.web.fc2.com

However the company stopped breaking out mobile revenue after the third quarter ofso we assume revenue growth has further declined. The chief reason for the mobile disappointment is likely because iPhone users show far more interest in WebMD than Everyday.

The Street Sweeper - 22nd Century (XXII) Announcements = Promos, Dilution, Institutional Selling

Everyday Health download rankings frequently fall below 1, in the health and fitness category: That compares with WebMD's app which consistently ranks around the top 73 downloads: An insidious threat has already taken a toll and is set up to kill much of the ability of sites like Everyday Health to make money from ads Ad-Blockers Gobble Profitability Pathway. The soft, scraping sound behind you is becoming more urgent. Rest assured the source of that cacophony is a clomping pair of red-splattered boots worn by zombie stock,Teck Resources Limited TCK.

Indeed, this stock appears to be one of those on the ragged edge of the looming apocalypse. The trick will be walking away from Teck as it leads a swarm of undead toward a cataclysm of unspeakable terror. To aid in that effort, TheStreetSweeper offers the top 10 bumps in the night for this stock.

The Canadian mining company focuses on coal for steel-making, copper and zinc through assets in Canada, the United States, Peru and Chile. The sales trend has been nothing but down, down, down for five years: SinceTeck has seen a staggering 28 percent drop in revenue.

The situation resulted in CEO Lindsay issuing a warning, "we have lowered our coal and copper cost guidance for the full year. Valuation Absurd; Profits Plunge. Yet the stock sports a ridiculously oversized forward price-to-earnings ratio of But Teck isn't even making a net income. Teck earning figures took an epic drop into the red in Shareholders continue to take it on the chin this year, too. In the second quarter, profit dropped But rather than driving a stake in Teck's heart, the terrible July 28 financials fueled the rocket ship: The desperate company has been deferring capital expenditures, gradually laying off 1, of its 3, employees, selling assets and even shutting down its Coal Mountain project, a British Columbia mine once anticipated to produce 2.

But even those efforts likely will not be enough for this commodity-dependent company. Such commodity businesses have taken a beating for a couple of years. Judging by the stock run, the market must have bought into the CEO's second quarter comments on his commodity business. Lindsay in a statement. But the world steel industry itself indicates the future appears gloomy. China has been Teck's chief customer. Yet the World Steel economics committee chairman, TV Narendran, said the greatest weakness in steel demand is expected to be in China: Growth for steel demand in all markets except China is expected in Annual steel product demand is expected to be Meanwhile, the company is already failing to generate cash.

That makes negative cash flow in each of the last three quarters TheStreetSweeper issues an alert for Airgain AIRG investors. This recent IPO has flown for no reason and now circumstances have aligned to suddenly take all the air out of Airgain. Nearly 3 million shares registered late Friday. The wireless network antenna seller has taken advantage of the high stock price to set up employees for more gains.

Almost two hours after the market closed on Friday, Airgain filed to register 2. The issuance represents a cost to current investors And that's not all! A second raft of potential dilution awaits investors, too. Roughly 1 million options are exercisable immediately, according to the chief financial officer's comments during the earnings call.

Those options appear to be awfully cheap These shares have been held since the IPO in August and will be available for trading as soon as the day lock-up period ends. Imagine all the champagne-cork flying and caviar gulping at insiders' New Year's Eve parties as they begin celebrating their potentially huge payday around Feb.

And an odd circumstance has developed right on top of the dilution concerns Coverage only from its own underwriting firms Other than the out-of-whack stock price, nothing seems to be going exactly right for Exact Sciences EXAS. In the 21 years since the Madison, Wisconsin company began trying to develop and sell a DNA-based colorectal cancer screening tool, it has produced three failures and one product whose fate remains to be seen.

PreGen-PlusEffipure and ColoSure initially attracted a partnership with commercial lab Laboratory Corporation of America Holdings LabCorp. Just a few years after the launch of PreGen-Plus, Exact got slapped with an FDA warning letter noting "serious regulatory problems. So LabCorp discontinued both PreGen-Plus and Effipure in June Finally, inLabCorp reported " no sales ," thus no royalties for Exact. Now LabCorp had its third failed product by Exact. About half-a-billion dollars had gone down the latrine by the time the company launched its most recent DNA-based colon cancer diagnostic, Cologuard, in The company was so desperate it funded its own study in hopes of getting good test results from Cologuard.

Because Exact spends so much to generate revenue. The self-funded study bummer is just part of what is not exactly right with Exact. Investors may find other viewpoints herewhile we consider other risks that could send their investment straight down the water closet.

Patients Resist Cologuard Requirement. Cologuard costs some 20 times greater than other stool tests. And it turns out that patients resist the stool sample collection and preparation required by Cologuard referred to below as sDNA.

That's according to doctors who wrote a clinician's guide to fecal blood testing that was published last April in the Southern Medical Journal: The requirement of collecting the entire stool and shipping the specimen for sDNA testing In fact, Exact has noticed the ewweeww factor with Cologuard - which still requires the "whole stool" collection used by its previous failed products.

Another concern is Cologuard's high level of false-positive results. That's according to final recommendations from the US Preventive Services Task Force USPSTF. The stock had moved on hope the panel's update to its earlier report would remove Cologuard from "alternative" testing to "recommended" testing.

But the final recommendation simply dropped the terms alternative and recommended. The USPSTF provided the table below, summarizing various screening techniques. USPSTFTheStreetSweeper note, click to see more. The task force also wrote that FIT-DNA Cologuard produces " True negative means the disease being tested for was not found.

False positive means the proportion of people who are actually free of the disease but test positive. The task force added that the FIT-DNA Cologuard false-positives mean "a higher likelihood of follow-up colonoscopy," an invasive procedure which has downsides of anxiety, discomfort and even morbidity. REN stock is primed and just one down-tick away from disaster. TheStreetSweeper issues this quick alert on this Denver-based oil and gas company that is still the same miserable money-loser it was a couple of weeks ago Here are TheStreetSweeper's top five reasons that we believe this stock is begging to tank: The company's production is substantially declining: Not surprisingly, financial results for 2Q were just as horrible as the production figures.

Revenue declined and negative earnings persisted. The company placed that vital information on page 4, well below the company cheerleading s tatements that began with: Because REN guys felt optimistic. And others piled on more unfounded optimism Chatter within chat rooms such as investorshub has heartily promoted REN to retail investors. Such attention is often a hallmark of a stock groomed to be a highflier one day, and doomed to be a lowdown loser the next.

Note that nobody talks about the company's financial condition or potential. It's all about the stock movement. Motley Fool also published a bullish piece here which helped rocket the stock, while the author suggested the company's optimistic production guidance was the primary driver. A major investor - SPO Advisory managed by John Scully - has found reason to sell REN stock.

SPO dumped 10 million shares in late April, severely trimming the investment firm's ownership: Indeed, institutional investors were selling out, pre- reverse-splitat nearly three times the rate of those taking new positions: Meanwhile, as a testiment to absurdity, REN is way above analysts' average one-year price target: Like a diabolic superhero, Rentech RTK has tried to leap tall financial issues with a single bound.

But now a ton of kryptonite is headed its way, promising to decimate the company stock in one fell swoop. TheStreetSweeper's executive bullet points summarize the superhuman problems that will chop this wood fiber company's stock into splinters: Meanwhile, here's a closer look at Rentech's stock slayers: Not So Super, After All: But an overly excited market rushed to pop up the stock without taking time to understand what's really behind that number.

The figure is just an illusion of profitability caused by a one-time tax gain. People didn't understand that Rentech's second quarter revenues actually swooped lower! TheStreetSweeper issues an investor alert for Resolute Energy Corp.

The stock jumped following the Aug.

The market pushed up Resolute and other oil companies' stock with the crude oil rally on Aug. Oil prices tumbled yesterday and, after the closing bell, Resolute filed notice that Nicholas Sutton will retire as CEO. Considering the stock price has nearly tripled this month, TheStreetSweeper thinks it wouldn't be a bad idea if he chooses to sell a bunch of shares and ride off into the sunset.

It's unclear how smoothly the company can replace the man who has been CEO since the company's founding in Sutton will stay on as executive chairman but the new chief executive will be Richard Betz, a manager since and chief operating officer since Below are five more big reasons TheStreetSweeper is warning investors that this stock will almost undoubtedly suffer a rapid, tooth-rattling drop from the current ridiculous levels.

The reverse split also helped improve the valuation following its latest New York Stock Exchange delisting notification received last November. The exchange will continue to monitor those factors. Within days after this stock split, investment analysts began lining up to put in their two-cents worth about Resolute. The very next month, the firm raised the PT two more times Despite no Resolute news and bad news about oil prices and the CEO departure just two days awayon Monday, Aug.

Wunderlich, Barclays and Johnson Rice each shared underwriting responsibilities for the company's We can only imagine that these firms would also be interested in handling any future underwriting duties. We couldn't blame Zagg Inc.

ZAGG if it's quietly suffering buyer's remorse. But the cell phone accessory company will really be in trouble when investors understand the reason for the disappointment The troubles can be traced back to shortly after February, when Zagg bought Mophie, maker of an iPhone battery case called Juice Pack Air. Mophie's pretty battery cases seemed to be flying off the shelves. Enter the PokemonGo craze. The augmented reality game launched July 6 and immediately became a phone battery hog.

Meanwhile, TheStreetSweeper examines why Zagg's stock is now incredibly risky. Set Up For Failure. As it turned out, Mophie had been losing multi-millions. Then two months later, after everyone had forgotten about management's estimates, the pro forma numbers came out.

Those exaggerated numbers have set Zagg up for failure Touted Growth Despite Deteriorating Business. Since sales turned out puny compared to those touted by management, the Mophie segment will have to sell a ton of cases this year: The Mophie segment must be gulping over those expectations Magellan Petroleum Corporation MPET threatens to become the poster child for the "good deal" gone bad. The plan is to build a liquefied natural gas terminal on leased acres in Louisiana.

The idea is stoked by a man who has been vilified by activist investor Carl Icahn. The stock has rocketed on this plan Meanwhile, TheStreetSweeper presents the immense risks facing MPET investors. At the core of the MPET merger is Driftwood LNG. Former Cheniere Energy CEO Charif Souki filed a request in May with the Federal Energy Regulatory Commission FERC to begin an environmental review process for Driftwood. The new, as-yet-unnamed company hopes to produce and export 26 million tons per year of LNG in facilities in southwest Louisiana.

Construction is hoped to begin in and will likely take seven yearswith the first plant operational in Company officials expect the project to become fully operational the second quarter of In contrast, Denver, Colorado based oil and gas company MPET has turned into a shell of a company forced to sell its assets to fund operations. The company operates under the cloud of going concern issues and earnings have been negative. The reverse takeover of MPET will allow Mr. Souki to take his new company public, Tellurian Investments, with business partner Martin Houston.

Just last December, billionaire shareholder Carl Icahn ousted Mr. Icahn continued his comments on Mr. Souki, according to Bloomberg: This is the problem.

Cheniere approached bankruptcy in as Mr. Souki developed a multibillion-dollar plan to import liquefied natural gas into America, but the U. Cheniere was left with huge, expensive LNG tanks and nearly empty pockets, as Forbes wrote. Souki pushed an even more expensive idea of exporting some of that U.

But the collapse in oil prices came as the costly plan was slowly unfolding. Cheniere shares fell by more than half inattracting Mr. Icahn's stake in the company in Augusttwo seats on the board and an interest in examining Mr. According to Bloomberg's April article, after Mr. Souki was fired, Mr. Icahn commented that Mr. Under the MPET deal, each share of Tellurian will be converted into the right to receive 1.

This dilutive deal is expected to be completed in the last quarter of Yes, that's million shares added to the 5. After a decade of controversy over its proposed Pebble mine, Northern Dynasty Minerals NAK is still absolutely nowhere. At first glimpse, unwary investors might expect significant news because the stock has practically doubled over a month to unsustainable levels.

The Pebble property covers square miles of land in Alaska, taking in at least 15 square miles for the proposed mine operation and tailings ponds.

The project would place one of the world's largest copper and gold mine against the world's largest salmon fishery and environmental concerns.

The project has not yet entered the permitting phase. So there's no real news now and this stock has no upward trajectory left. Meanwhile, TheStreetSweeper highlights seven key downside risks to NAK investors: Momentum traders keyed in on the stock on Monday, July 11, when Insider Monkey noted that Sprott Asset Management disclosed a 5.

Volume jumped to 5. But by July 29, Sprott had already begun selling part of its NAK stock. The firm disclosed its ownership had dropped to 3. According to his comments on BNN: One of the biggest, and highest grade copper gold deposits in the world, it is subject to a legal and political dispute. In our opinion, a political resolution with Alaskan Indigenous owners would solve the legal dispute, and both sides have ample incentive to reach a mutually beneficial agreement.

This will be a binary outcome, a huge win, or a substantial loss, and the time frame is indeterminate. Some of the air had gone out of the stock from the time of the Sprott disclosure a month earlier until Mr. Rule's suggestion last week But NAK again rose - notwithstanding the fact that Sprott Resource Corp. Traders apparently also didn't notice Sprott's stock chart: Indeed, the suggestion from Sprott advanced the NAK stock runup. Congratulations to those who got in on the momentum trading over the past four weeks or so.

Keep in mind that this trade activity is based on - indeed in spite of - the same old, same old The day after Mr. Rule included NAK among his investment suggestions, NAK finally had some real news.

NAK filings also disclosed it is quickly burning through its minimal cash stash: It seems the market missed the Santa Jose, California firm's comment near the bottom of the press release that it has a new investment Maybe the market is beginning to get bleary eyed at yet another overly optimistic spin: We are poised to expand our company and accelerate the pace of licensee expansion to make our vision of a ubiquitous WattUp ecosystem a reality and solidify our position as market leader.

Meanwhile, TheStreetSweeper alerts investors to four good reasons this stock is poised to wreck investment portfolios: WATT keeps running to the stock trough in search of more cash. And each time the company goes back for more, the quality of the stock offering declines.

Oppenheimer, Roth, National Securities. Ladenburg Thalmann, Roth, National Securities Note: Ascend Legend private purchase. High Claims; Delivery's Tougher. WATT doesn't need the fluff pumped out by professional promoters, such as those who hyped the stock in and here.

It can be overly optimistic all by itself, thank you very much. Ascend isn't a multi-billion company. WATT managers consistently talk as SA author Paulo Santos notes about commercialization being just around the corner Did not push out product time line. But changed the topic from full scale WattUp transmitter to mini WattUp transmitter. The WattUp enabled Midsize transmitter applications will be shipping in late and the Full-size WattUp transmitters will be shipping in early WATT bears an unfortunate resemblance to Second Sight Medical Products EYES.

TheStreetSweeper issues an investor alert on Image Sensing Systems ISNS. The company focuses on software-based detection products for the transportation industry. Incredibly, the stock is flying following a dull announcement that it is expanding its product offering here. But investors need to be alert to the company's extreme risks at this point, including: ISNS is burning the cash. This suggests a capital raise may be imminent. However, company revenue declined from a year earlier, while cost of revenue increased: Unfortunately, the year's revenue was the lowest reported in 8 years.

TheStreetSweeper issues an investor alert for Odyssey Marine Exploration OMEX. The shipwreck exploration company is rapidly turning into an epic shipwreck that will leave unwary investors drowning in its wake. Financial distress has forced this Tampa, Florida company to essentially give up salvaging shipwrecks in December to re-focus on mining underwater phosphates in Mexican waters.

But that plan was derailed six months ago when the Mexican government rejected the company's environmental application to dredge in the "Don Diego" deposit.

Let's look more closely at OMEX, most likely the worst company we've ever considered Virtually No Cash Left. Today's investors might be surprised to learn that OMEX has operated as a hobby for the past decade, as shown by consistent yearly net losses. Company SEC filings, hereherehere. Those losses reflect OMEX' ongoing predicament of cash burn exceeding available cash: The company managed to add to cash and cut debt by selling its exploration boat, headquarters building and shipwreck inventory in December Company filings say now there's no remaining inventory.

The loan allows OMEX to limp along another quarter until the wolves line up at the doorstep again So OMEX is left with two choices: It must get significant financing, likely via convertible shares When the stock goes to the bulletin board, the show's over. And the stock we believe is left to trade for about 50 cents apiece. Broadwind Energy's BWEN chief executive recently commented, "I am tempted to say everything went wrong. The CEO referred to production problems when she made that comment during a recent earnings call.

But those words beautifully sum up Broadwind's past and present condition. The executive behind those words is Stephanie Kushner. She settled SEC charges just last year - along with Broadwind and a former CEO - related to allegedly keeping investors in the dark about Broadwind's financial deterioration. Today, the Cicero, Illinois wind tower support manufacturer remains a disaster, with operating losses percent worse than a year earlier.

Regardless, Broadwind stock has risen Meanwhile, TheStreetSweeper presents the top eight reasons we believe an investment in Broadwind will soon be gone with the wind: Broadwind's business is so poor that even at near-peak production of towers inthe company still lost money hand over fist. Broadwind is twisting and flailing like a mosquito in a tornado, thanks to some basic problems One massive problem is that Broadwind is selling a commodity weighed down by terrible gross margins.

Margins for the year hit the lowest level in 4 years The company did manage to cut costs and raise the margin slightly last quarter. But cost cutting can go only so far. Sales, general and administrative costs were 8. Not Like Canning Beans. But the challenge will be dealing with the combination of terrible margins and production problems. Ms Kushner talked about those production killers during the fourth quarter earnings call here: The majority of our problems are in two key areas: Additionally, she suggested the Abilene, Texas plant layout was poor and cramped, and the workers were relatively inexperienced.

Ocean Power Technologies OPTT is creating waves alright Over 32 years, the company has failed to turn electricity-generating ocean wave power into a real business. But the company has created waves over the years by recycling old "news. Yet the stock recently lifted off and floated to price levels not seen in over a year. TheStreetSweeper alerts investors about what's really behind this rally On June 1the stock shot up some percent on a company press release announcing Ocean Power's lease agreement with Mitsui for a power buoy "planned to be deployed off Kozu-island All well and good, right?

Except that Mitsui deal is not new. The companies began working together eight years ago. But in OctoberOcean Power reeled out a strikingly similar press release which said the company agreed with Mitsui " to cooperate in the development and commercialization" of the power buoy. Ocean Power's habit of recycling old news goes back several years.

Inthe company announced it clinched a deal with Lockheed Martin for a demonstration project in Australia. That worked so well, it spun out the same news two years later here. The deal fell dead in the water in Pitiful Sum, Many Years In The Making. One thing about the recent, much-trumpeted Mitsui deal is amazing. It has taken Ocean Power three years to progress from agreeing, to agreeing some more and planning to deploy a power buoy.

Mitsui apparently considers this arrangement no more than a science experiment; the Mitsui website doesn't even mention Ocean Power and its ballyhooed agreement. Mitsui Engineering and Shipbuilding. Alarmingly, Mitsui's sub-million-dollar contract is Ocean Power's " one revenue producing contract. Lately, Ocean Power has needed to lean heavily on its one viable deal July 14 Press Release. Ocean Power's July 14 press release should have been considered skeptically.

You see, the very next day, the company was scheduled to release its fiscal year financial report. And that report was filled with shockers. Looking through Vuzix VUZI eyewear, we see a future clouded by an SEC inquiry, paid promotions, more stock-diluting raises and more investor money thrown down the drain. Here are details on the top five reasons that TheStreetSweeper wants to toss out Vuzix and its goofy, not-that-smart eyewear: On May 24the Securities and Exchange Commission notified Vuzix that the company is under inquiry.

On July 6, Vuzix finally mentioned the SEC inquiry. Instead of immediately disclosing this crucial matter in an 8-K, the company waited six weeks to disclose the news near the bottom of its prospectus.

First, let's look at recent events and then we'll put it all together After The SEC Notification. On June 9professional promoters pushed a video news release promoting a so-called collaborative agreement between Vuzix and an undisclosed party. The CEOLive host quickly mentions that no licensing agreements or technology transfers have happened; but the parties have agreed to work toward a prototype; and that this "big" announcement is really just a follow-on effort.

So this hype appears to be an oddly timed regurgitation of an old, small, tenuous deal. Regardless, this information helped fuel the stock rally. Incredibly, that June 9 promotion hit about two weeks after Vuzix got the SEC inquiry letter. At the time of the promotionapparently only Vuzix managers knew about the SEC's inquiry. Likewise, many didn't realize the company had been struggling and stumbling along since before it ever began selling smart glasses in late The company also reported dismal losses and gross margins for versus And Vuzix sales - which were already pathetic - have continued to deteriorate: Odyssey Marine Exploration OMEX dives to recover treasures from shipwrecks.

But its current project may be the most challenging yet While investors may find other viewpoints hereTheStreetSweeper sees one titanic disaster in the making. So OMEX appears to be operating on fumes.

At the same time, OMEX is struggling with debt deals and owns virtually no assets. OMEX's financial lifeboats recently have been anchored on expectations that Mexico approve the Don Diego permit. But Mexican authorities denied this critical application. The Don Diego represents a Hail Mary business restructuring for OMEX and, in our view, another reason for investors to brace for failure.

Way back inthe company began navigating the thrilling but choppy waters of undersea excavation and recovery. Inthe company began a very public 5-year battle with Spain over gold and silver recovered from the "Black Swan" warship. In the midst of that public drama, the company restructured operations in to focus on deep water seabed exploration of minerals. Then on April 11, Mexico denied the company's environmental permit application amid concerns about the environmental impact on sea turtles.

TheStreetSweeper issues an investor alert on Digital Ally DGLY. Shares in consistently unprofitable Digital Ally have rocketed following last week's shooting rampage that left five police officers dead and more fighting for their lives.

As the gunman blasted away and the crowd panicked, police body cameras supplied by Taser International TASR captured video of the scene. With the nation focused on Dallas and other shootings, it's not too surprising that Taser shares soared 5.

TheStreetSweeper's executive bullet points below summarize why we expect the stock to plummet back to earth: DGLY stock is up after the market has mistakenly aligned the stock with body camera market leader Taser International. Compared with Taser, DGLY's product costs nearly two times more and offers inferior resolution, battery life and field of view. DGLY's revenue has been dropping over the last 4 quarters; earnings remain negative.

In contrast, Taser offers positive earnings and revenue is nearly 10 times greater than DGLY. Taser Owns The Market. The company's nemesis Taser International initially gained attention with its stun guns. But now the company has catapulted into the market-leading position for body cameras, controlling three-fourths of the body camera business in the United States. Cops in cities from Dallas to Los Angeles to Washington wear Taser's state-of-the-art Axon body cameras.

A key component is Taser's "Evidence. Meanwhile, Digital Ally is focusing on a different product. Though the company began in as a bow-hunting product company, init began shipping what is still its primary product - the old-time, in-car video camera. Yet investor and consumer interest is clearly focused on high-tech body cameras. Somehow Digital Ally has gotten swept up in the excitement even though its body worn camera called "FirstVu HD" and "FirstVu" is a tiny portion of its business.

Digital Ally has found that its body camera sales are seriously lagging behind its old in-car products. Worse yet, last quarter, the body cameras lost even more ground: Though Digital Ally is a minor player in the body camera business, its cameras cost surprisingly more than Taser's: Digital Ally's specs fall short, too.

These cameras depend on an external battery which provides less than half the battery life of Taser's camera. Taser's video resolution and field of view also dwarf its small competitor's specs.